Regeneron (REGN) Tops Q2 EPS by $8.11, Sales Pounce Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Regeneron Reports Second Quarter 2021 Financial and Operating Results
August 5, 2021 6:30 AM EDTTARRYTOWN, N.Y., Aug. 5, 2021 /PRNewswire/ --Â Â
Second quarter 2021 revenues increased 163% to $5.14 billion versus second quarter 2020 including $2.76 billion attributable to REGEN-COVTM(2); revenues excluding REGEN-COV(1)(2) increased 22% Second quarter 2021 EYLEA® U.S. net sales increased 28% versus second quarter 2020 to a record $1.42 billion Second quarter 2021 Dupixent® global net sales(3), which are recorded by Sanofi, increased 59% to $1.50 billion versus second quarter 2020 Second quarter 2021 GAAP diluted EPS was $27.97 and non-GAAP diluted EPS(1) was $25.80 FDA updated REGEN-COV Emergency Use Authorization (EUA) with lower dose, subcutaneous administration, and... More